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Hyperhalophilic archaebacteria exclusively produce sn2,3 diphytanylglycerol diether
archaeolipids, unique structures absent in bacteria and eukaryotes. Nanovesicles
made of archaeolipids known as nanoarchaeosomes (nanoARC), possess highly stable
bilayers, some of them displaying specific targeting ability. Here we hypothesize that
nanoARC made from Halorubrum tebenquichense archaebacteria, may constitute
efficient carriers for the TLR7 agonist imiquimod (IMQ). NanoARC-IMQ takes
advantage of the intense interaction between IMQ and the highly disordered, poorly
fluid branched archaeolipid bilayers, rich in archaeol analog of methyl ester of
phosphatidylglycerophosphate (PGP-Me), a natural ligand of scavenger receptor A1
(SR-A1). This approach lacks complex manufacture steps required for bilayers labeling,
enabling future analytical characterization, batch reproducibility, and adaptation to
higher scale production. SR-A1 mediated internalization of particulate material is mostly
targeted to macrophages and is extensive because it is not submitted to a negative
feedback. A massive and selective intracellular delivery of IMQ may concentrate its
effect specifically into the endosomes, where the TLR7 is expressed, magnifying its
immunogenicity, at the same time reducing its systemic bioavailability, and therefore it’s
in vivo adverse effects. NanoARC-IMQ (600–900 nm diameter oligolamellar vesicles of
∼−43mV Z potential) were heavily loaded with IMQ at ∼44µg IMQ/mg phospholipids
[∼20 folds higher than the non-SR-A1 ligand soyPC liposomes loaded with IMQ
(LIPO-IMQ)]. In vitro, nanoARC-IMQ induced higher TNF-α and IL-6 secretion by J774A1
macrophages compared to same dose of IMQ and same lipid dose of LIPO-IMQ. In vivo,
3 subcutaneous doses of nanoARC-IMQ+ 10µg total leishmania antigens (TLA) at
50 µg IMQ per Balb/C mice, induced more pronounced DTH response, accompanied
by a nearly 2 orders higher antigen-specific systemic IgG titers than IMQ+TLA and
LIPO-IMQ. The isotype ratio of nanoARC-IMQ+TLA remained ∼0.5 indicating, the
same as IMQ+TLA, a Th2 biased response distinguished by a pronounced increase
in antibody titers, without negative effects on splenocytes lymphoproliferation, with a
Parra et al. Macrophage Targeted Imiquimod
potential CD8+LT induction 10 days after the last dose. Overall, this first approach
showed that highly SR-A1 mediated internalization of heavily loaded nanoARC-IMQ,
magnified the effect of IMQ on TLR7 expressing macrophages, leading to a more intense
in vivo immune response.
Keywords: archaeolipids, scavenger receptor, toll like receptor, endocytic internalization, interleukin 6
INTRODUCTION
Archaebacterias are a unique and appealing source of new
biomaterials. The diphytanylglycerol diether nature of
archaeolipids, displaying a stereoisomerism different from that
of lipids produced by bacteria and eukaryotes is responsible for
the peculiar “membrane anomaly” described for Archaebacterias
bilayers (Eme et al., 2017). In water media, polar archaeolipids
form archaeosomes or nanoarchaeosomes (nanoARC),
micrometer or submicrometer mean sized nanovesicles
respectively, that chemical and biophysically differ from
ordinary liposomes. In particular, archaeosomes prepared with
polar archaeolipids extracted from Halorubrum tebenquichense
contain ligands of SR-A1.
In this work we hypothesize that nanoARC prepared with
lipids extracted from Halorubrum tebenquichensemay constitute
carriers that solve the problem of formulating the TLR7 ligand
imiquimod (IMQ). IMQ is an immune response modifier,
approved by the FDA for the treatment of actinic keratosis,
superficial basal-cell carcinoma lesions, besides of various off-
label uses on precancerous and cancerous skin lesions (Papadavid
et al., 2007). Its use in preclinical transcutaneous immunization
is limited however, since in the presence of a cytotoxic T
lymphocyte (CTL) epitope, the elicited immune response decays
within a few days, requiring co-stimulation via CD40 for
instance, to enhance the primary CTL response and effective
formation of memory CTL (Warger et al., 2007). Aldara, the
same as other preclinical particulate carriers for IMQ so far
developed, such as solid lipid nanoparticles (Zhou et al., 2007),
liposomes (Fox et al., 2014), nanogels (Stein et al., 2014), or
emulsions (Lopez et al., 2017), release IMQ into the application
site microenvironment upon structural degradation of the carrier
particle (Chollet et al., 1999). The IMQ spreading beyond the
application site has been identified as a source of systemic
toxicity (Steinhagen et al., 2011; Mifsud et al., 2014). Here
we propose to modify the pharmacodynamics of IMQ by
loading it within nanoARC. We hypothesize that nanoARC,
by being naturally targeted to SRA-1 expressing macrophages,
would deliver the carried IMQ into the endo-lysosomal pathway
and therefore concentrate its effect into a specific intracellular
site. IMQ induces a moderate TLR7-independent inhibition
on adenylyl cyclase activity, impairing a negative feedback
mechanism that normally limits inflammatory reactions (Schön
et al., 2006; Schön and Schön, 2007). The avoidance of this
inhibition by SR-A1 targeted delivery of IMQ and the lack
of isostearic acid responsible for additional TLR7-independent
inflammatory effects (Walter et al., 2013), would lower the
chances of systemic inflammation a potential toxicity (Heikkinen
and Susitaival, 2011). Switching from a diffusion mediated cell
entering mechanism for free IMQ, to an endocytic uptake
of nanoARC carrying IMQ (nanoARC-IMQ) by SR-A1+ cells
would lead to a massive delivery IMQ to the endo-lysosomal
system, concentrating its activity only on SR-A1+ and TLR7
expressing cells. This would improve IMQ immunogenicity,
reducing at the same time its systemic bioavailability, and
therefore it’s in vivo adverse effects. Formulating the weak
base IMQ [(1-(2-methylpropyl)-1 -imidazo [4,5-c] quinolin-4-
amine] however, results a challenging task (Gogoll et al., 2012).
There are a few organic agents (Chollet et al., 1999) capable
of efficiently dissolve IMQ, such as the isostearic acid (ISA),
a relatively toxic constituent of the poorly stable commercial
creamAldara (Chollet et al., 1999). The unique structural features
of archaeolipid bilayers may help to partition the IMQ, ruling
out the need for ISA. To the best of our knowledge, this is
the first approach where a ligand expressed on the surface of
nanoARC is combined with an immunomodulator, to render
double targeted nanoARC. The lack of complex manufacture
steps needed to covalent labeling is an additional benefit that
will facilitate analytical characterization, batch reproducibility
and adaptation to higher scale production of such formulation
(Korsmeyer, 2016; Landesman-Milo and Peer, 2016). Here we
will prepare and structurally characterize nanoARC-IMQ and
test its in vitro and in vivo immunomodulatory performance
upon 3 subcutaneous doses mixed with model mucocutaneous
leishmania parasite proteins in Balb/C mice.
MATERIALS AND METHODS
Materials
Soybean phosphatidylcholine (SPC, purity > 90%) was a gift
from Lipoid (Ludwigshafen, Germany). Imiquimod (purity
>98%) was a gift from Laboratorio Lazar (Buenos Aires,
Argentina). MONTANIDE
TM
ISA 763A VG was from Seppic
(Puteaux, France). Ficoll was from GE Healthcare (Munich,
Germany). Hypaque was from Winthrop Products (Buenos
Aires, Argentina). Roswell Park Memorial Institute (RPMI)
1640 medium was from Gibco, Life Technologies (New York,
USA). Antibiotic/antimycotic solution (penicillin 10,000 IU/mL,
streptomycin sulfate 10 mg/mL, amphotericin B 25µg/mL),
glutamine, and trypsin/ethylenediamine tetraacetic acid were
from PAA Laboratories GmbH (Pasching, Austria). Fetal bovine
serum (FBS) was from Internegocios, Cordoba, Argentina.
Concanavalin A (ConA), Phorbol 12-myristate 13-acetate
(PMA), Laurdan, saponin, Carboxy fluorescein succimidil ester
(CFSE), 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyl tetrazolium
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bromide (MTT), and 2, 2′-azino-bis (3-ethylbenzthiazoline-6-
sulphonic acid (ABTS) were from Sigma-Aldrich (San Diego,
USA). The other reagents were analytic grade from Anedra,
Research AG (Buenos Aires, Argentina).
Archaebacteria Growth, Extraction, and
Characterization of Total Polar
Archaeolipids
Halorubrum tebenquichense archaeas, isolated from soil samples
of Salina Chica, Península de Valdés, Chubut, Argentina were
grown in 15 L of basal medium supplemented with yeast
extract and glucose at 37◦C in a 25 L home-made stainless-steel
bioreactor. Cultures were monitored by absorbance at 660 nm
and harvested after 96 h growth. Total lipids were extracted from
biomass using the Bligh and Dyer method modified for extreme
halophiles and the Total Polar Lipid (TPL) fraction was collected
by precipitation from cold acetone (Kates and Kushwaha, 1995).
Between 400 and 700mg of TPL were isolated from each culture
batch. The reproducibility of each TPL extract’s composition was
routinely screened by phosphate content (Böttcher and Pries,
1961), and electrospray ionization mass spectrometry (ESI-MS)
as described in Higa et al. (2012).
Preparation of Total Leishmania
amazonensis Antigen
Total L. amazonensis antigen (TLA) was prepared as described
in Cargnelutti et al. (2016). Briefly, log-phase promastigotes of L.
(L.) amazonensis were harvested by centrifugation, washed three
times with PBS and disrupted by six to eight cycles of freezing
(−80◦C) and thawing (56◦C). Protein contents of the TLA were
estimated by the bicinchoninic acid assay (Micro BCATM Protein
Assay Kit, Thermo Fisher Scientific Inc., Massachusetts, USA).
The antigens were kept frozen at−70◦C until use.
Preparation of Nanoarc-IMQ and LIPO-IMQ
Nanoarchaeosomes made of TPL from Halorubrum
tebenquichense (nanoARC), nanoarchaeosomes loaded with
IMQ (nanoARC-IMQ), liposomes made of SPC (LIPO) and
liposomes loaded with IMQ (LIPO-IMQ) were prepared by the
lipid film hydration method. Briefly, to prepare nanoARC and
LIPO, 50mg of TPL or SPC, respectively, in 0.5ml chloroform:
methanol 1:1 (v/v) were poured in 2ml U bottom shaped
Eppendorf tube. The lipid film was formed upon evaporation
of the organic solvent under N2 flush. Then, the films were
hydrated with 1ml of 10mM Tris-HCl buffer pH 7.4 with 0.9%
w/w NaCl (Tris-HCl buffer).
To prepare nanoARC-IMQ and LIPO-IMQ, the lipid films
were hydrated with 1ml of 2 mg/ml IMQ in 100mM lactic acid
(LH) under stirring.
To remove non-incorporated IMQ, nanoARC-IMQ and
LIPO-IMQ were washed 3 times by 15min centrifugation
at 35,000 g, followed by supernatant removal and pellet
resuspension in identical volume of LH up to no IMQ was
detected in the washingmedia. Then the pellets were resuspended
in 1ml Tris-HCl buffer. Finally, nanovesicles were sonicated
1 h in bath sonicator (80W, 80KHz). To assess for a potential
IMQ release from nanovesicles caused by sonication, the
IMQ/phospholipids ratio was measured in nanoARC-IMQ and
LIPO-IMQ prepared as stated above, excepting that half of the
final pellets were washed in Tris-HCl buffer and half in LH. The
IMQ/PL ratio is accurately estimated in LH, where the IMQ
remains soluble, not co-precipitating with the pellets. Instead, an
over estimation of the IMQ/PL ratio may occur in pellets washed
in Tris-HCL buffer, where insoluble IMQ released from bilayers
may co-precipitate with the pellets. Phospholipids and IMQ in
pellets and supernatants were quantified as described below. The
IMQ/PL of each pellet was calculated before and after sonication.
To assess for a potential IMQ release from nanovesicles after
dilution, 1ml of freshly prepared nanoARC-IMQ and LIPO-IMQ
were washed by centrifugation by 15min at 35,000 g followed by
supernatant removal and pellet resuspension in 900 µl Tris-HCl
buffer at 6, 24, and 48 h. Phospholipids and IMQ in supernatants
were quantified as described below.
Characterization of Nanovesicles
Phospholipids and Imiquimod Quantification
Phospholipids (PL) were quantified employing a Böttcher
microassay (Böttcher and Pries, 1961).
IMQwas quantified by UV-vis spectroscopy at λ 305 nm upon
complete disruption of nanovesicles in ethanol:chlorhydric acid
98:2 v/v.
The absorbance of the sample was compared to a standard
curve prepared with IMQ dissolved in ethanol:chlorhydric acid
98:2 v/v. The standard curve was linear in the range 1.25–
20µg/ml IMQ with correlation coefficient of 0.998.
Size and Z Potential of Nanovesicles
Size and Zeta potential were determined by dynamic light
scattering (DLS) and phase analysis light scattering (PALS),
respectively, using a nanoZsizer apparatus (Malvern Instruments,
Malvern, United Kingdom). Nanovesicles were diluted 1:20 in
Tris-HCl buffer (50 µl of samples with 950 µl of Tris-HCl buffer)
for size and Z potential determinations.
Laurdan Generalized Polarization (GP) and
Fluorescence Anisotropy (FA) of Nanovesicles
The order and fluidity of nanovesicles bilayers before and
after centrifugation were assessed by determining GP and
FA, respectively of Laurdan. Briefly, nanovesicles were labeled
with Laurdan by mixing 10 µl of 120mM Laurdan in methanol
with a volume of nanovesicles sufficient to render a 1:20 mol:mol
Laurdan:lipids ratio.
GP was calculated using the following equation:
GP = −I490/I440 + I490 (1)
Where I440 and I490 are the fluorescence intensities at λem =
440 nm and λem = 490 nm, respectively and obtained from the
spectra between 400 and 520 nm at λex = 364 nm (Slitex: 5.0 nm
and Slitem: 10.0 nm. Scan Speed: 100 nm/min).
FA was calculated by the fluorimeter software according to the
following equation:
FA = (I0 − GI90)/(I0 + 2GI90) (2)
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Where I0 and I90 are the fluorescence intensities at λem = 440 nm
with λex = 364 nm and the excitation polarizer oriented at 0
and 90◦, respectively. The correction factor (G) was obtained
from the ratio of emission intensity at 0 and 90◦ with the
excitation polarizer oriented at 90◦ (after subtraction of scattered
light).
GP and FAmeasurements were carried out with a fluorescence
spectrometer LS 55, PerkinElmer.
Cryo-Transmission Electron Microscopy
Samples were prepared in a controlled environment vitrification
system, equilibrated at 22◦C and analyzed using a TALOS
F200C (Thermo Fischer Scientific, USA) electron microscope
operating at 200 kV. Images were acquired using a CMOS
camera Ceta 16M 4k x 4k pixels (Thermo Fischer Scientific,
USA). Images were not processed after acquisition. Sample
preparation and data acquisition were performed at the Electron
Microscopy Laboratory (LME)/Brazilian Nanotechnology
National Laboratory (LNNano).
Cytotoxicity and TNF-α and IL-6 Induction
on J774A1 Macrophages
Immortalized murine Balb/C macrophages J774A.1 (ATCC R©
TIB-67TM) were kindly supplied by Dr Erina Petrera (Facultad
de Ciencias Exactas y Naturales Universidad Nacional de Buenos
Aires, Argentina). The cells were maintained in RMPI 1640
supplemented with 10% FBS, 100 U/ml penicillin, 100µg/ml
streptomycin and 2mM L-glutamine (complete RMPI medium)
in a humidified atmosphere of 5% CO2 at 37◦C.
The viability of J774A.1 cells upon 24 h incubation with 5,
0.5, 0.25, and 0.025 µg IMQ/ml (IMQ1,2,3, and 4, respectively),
100 and 10 µg PL/ml nanoARC (nanoARC1 and nanoARC2),
100 and 10 µg PL/ml nanoARC-IMQ (nanoARC-IMQ1 and
nanoARC-IMQ2), 100 and 10 µg PL/ml LIPO (LIPO3 and
LIPO4), and 100 and 10 µg PL/ml (LIPO-IMQ3 and LIPO-
IMQ4) was measured by the MTT assay. The MTT test measures
the activity of mitochondrial dehydrogenases and therefore
reflects both cytostatic and cytotoxic effects.
To visualize potential morphological changes suffered by
J774 A1 cells upon 24 h incubation with the above-mentioned
samples, a series of bright field microscopies were taken. To that
aim, 150,000 cells were seeded in 300µl RPMI culturemedia with
5% FBS per well in a 24 wells plaque. The cells were cultured
in CO2 at 37◦C along 24 h. Afterwards the culture media was
extracted, and samples diluted in culture media were added and
cultured along 24 h in identical conditions. Before each picture
was taken, the supernatant was removed and two washes with
non-sterile PBS were performed. The bright field microscopy
images at 20X magnification were taken employing a CytationTM
5 Cell Imaging Multi-Mode Reader (BioTek Instruments, Inc.,
Winooski, VT, USA) equipment. The assay was performed by
triplicate, employing 3 independent batches; two pictures per well
were taken and the more representative images were selected.
The release of TNF-α and IL-6 in supernatants was evaluated
after incubation with nanovesicles on J774A.1. LPS at 1µg/ml
was used as positive control. Mouse TNF-α and IL-6 in
supernatants, were measured by enzyme-linked immunosorbent
assay (ELISA) (BD, OptEIA, BD Biosciences, CA, USA),
following the manufacturer instructions.
Immunization
Animals and Immunization Schemes
6–8 weeks female BALB/cAnN mice were obtained from Centro
Atómico de Ezeiza; Comisión Nacional de Energía Atómica
(CNEA). Five mice randomly selected were distributed per box
and housed in a ventilated room under controlled conditions,
at constant temperature of 22◦C, 12/12 h light/darkness cycles
and food and water ad libitum. This study was carried out in
accordance with the principles of the Institutional Committee
of Care and Use of Laboratory Animals (CICUAL) of the
National Quilmes University, that follows the International
guiding principles for biomedical research involving animals of
the Council for International Organization of Medical Sciences
and the International Council for Laboratory Animal Science
(CIOMS-ICLAS). The protocol was approved by CICUAL of the
National Quilmes University.
A first series of subcutaneous immunization employing
five mice per group was performed on days 0, 14, and 28.
Immunization were carried out with 10µg TLA physically mixed
with MONTANIDETM ISA 763A VG (ISA 763) (prepared as
a water in oil emulsion at adjuvant:antigen 7:3 v:v) according
to the manufacturer instructions (Technical Bulletin, Seppic,
Puteaux, France), or mixed with 50 µg IMQ either free (a 1:10
Tris-HCl buffer IMQ dilution from a 10 mg/ml IMQ stock
solution in 100mM LH) or from the following formulations:
nanoARC-IMQ, ARC+IMQ, LIPO-IMQ, LIPO+IMQ (where
nanoARC-IMQ+TLA = IMQ loaded in nanoARC mixed with
TLA; ARC+IMQ+TLA = a mixture of IMQ, nanoARC and
TLA; LIPO-IMQ+TLA = IMQ loaded in liposomes mixed with
TLA and IMQ+LIPO+TLA= a mixture of IMQ, liposomes, and
TLA).
A second series of subcutaneous immunization was
performed following the same time schedule, this time
with nanoARC-IMQ+TLA, nanoARC+IMQ+TLA,
LIPO-IMQ+TLA, ISA763+TLA, IMQ+TLA, and TLA.
DTH
Delayed type hypersensibility reaction (DTH) was tested 10 days
after the last immunization (day 38), according to Luo and Dorf
(2003) with some modifications. Briefly, 10 µg of TLA diluted
in 30 µl of PBS was injected subcutaneously into the dorsal left
footpad of each mice. After 24 h, right and left footpad thickness
was measured with a manual caliper. The swelling response was
calculated subtracting the right footpad thickness (baseline) from
that of the left footpad (injected with TLA).
Humoral Response
Blood was collected frommice tail veins at day 38 and IgG, IgG1,
and IgG2a antibody responses were measured by enzyme-linked
immunosorbent assay (ELISA) in serum samples. Briefly, high-
affinity 96 wells plates were coated overnight at 4◦Cwith 100µl of
TLA (3 µg/well) in carbonate-bicarbonate buffer (pH 9.6). After
washing three times with PBS with 0.05% Tween 80 (PBST), non-
specific sites were blocked during 1 h at 37◦C with 0.1% BSA in
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PBST (PBST-BSA). After another series of washes with PBST, 100
µl of three-fold dilutions of serum in PBST-BSA were incubated
during 1 h at 37◦C. Then, the plate was washed three times
with PBST and incubated during 1 h at 37◦C with horseradish
peroxidase-conjugated goat anti-mouse total IgG (Millipore-
Chemicon International, Temecula, USA) diluted 1:5,000 in
PBST-BSA. To determine the antibody isotyping, horseradish
peroxidase-conjugated rat anti-mouse IgG1 or IgG2a revealing
antisera (PharMingen, San Diego, USA), diluted 1:5,000, were
used. The plates were further washed and incubated with
ABTS for 15min at room temperature (20◦–25◦C) in the dark.
The absorbance was measured at 405 nm using a microplate
reader. Antibody titers were represented as end-point dilutions
exhibiting an optical density of 0.3 units above background.
IFN-γ in Splenocytes Supernatant, Intracellular IL-10
and IL-12 Cytokines
At day 38, the spleens of mice immunized with nanoARC-
IMQ+TLA, nanoARC+TLA, ISA 763+TLA were removed
aseptically and splenocytes were obtained using a Ficoll-Hypaque
gradient, as described by Böyum (1968). Briefly, spleens were
disaggregated on a metal mesh employing non-supplemented
RPMI media. The splenocytes were isolated by centrifuging
30min at 500 g in a Ficoll-Hypaque gradient (1.098 g/ml density)
in a Gelec G144d centrifuge. The resultant pellet was washed
twice with RPMI and finally suspended in supplemented RPMI
(10% SFB; 100 U/ml penicillin; 100 mg/ml streptomycin; 50µM
2-mercaptoethanol). The cells were counted in a Neubauer
chamber employing Türk dye and seeded in 96 wells U shape
bottom plate at a density of 1 × 106 cells per well in a final
volume of 200 µl. The cells were stimulated in vitro with TLA (3
µg/well) or concanavalin A (1 µg/well) as positive control. Non-
stimulated cells were used as negative control. Supernatants were
collected after 48 h incubation at 37◦C in a humified chamber
containing 5% CO2. The release of IFN-γ in cells supernatant
was measured by ELISA (BD OptEIA
TM
, BD Biosciences, San
Jose, USA) following the manufacturer instructions. Absorbance
measurements were carried out at 450 nm in a microplate reader.
To measure intracellular cytokines, cells were marked
with FITC conjugated anti-MHCII(I-Ad) and fixed in 1%
paraformaldehyde. Then, cells were permeated with 0.5%
saponin in PBS and intracytoplasmic marking of IL-10 and IL-12
was done using PE conjugated antibodies (Biolegend, San Diego,
USA). For this, cells were previously incubated during 4 h with
Brefeldin A (Thermo Fisher Scientific, Waltham, USA) to inhibit
cytokines liberation to external medium. Cytokine production
analysis was done with a FACScan flow cytometer and CellQuest
software. Results were shown as the percentage of positive cells
for each marker.
Splenocytes Surface Markers
Splenocytes from immunized and from non-immunized mice
were marked with fluorescent surface membrane monoclonal
antibodies (FITC conjugated anti-CD8, anti-MHCII(I-Ad)
and anti-CD11c; PerCP conjugated anti-CD4 and anti-B220;
PE conjugated anti-CD11b) (BioLegend, San Diego, USA)
according to Foster et al. (2007). Briefly, cell suspensions were
incubated with the indicated antibodies, diluted in PBS at 4◦C
during 30min and then washed with PBS and fixed in 1%
paraformaldehyde. Cell surface markers analysis was done with a
FACScan flow cytometer and CellQuest software (BD Bioscience,
San Jose, USA). Results are shown as the percentage of positive
cells for each marker.
Lymphocyte Proliferation Assay
Antigen specific cell response was also evaluated by a lymphocyte
proliferation assay using 5 nM of CFSE, according to Lyons
and Parish (1994). Sixty days post-immunization, splenocytes
from immunized and from non-immunizedmice were harvested.
Spleen cells were incubated with CFSE during 30min at 37◦C
and then washed twice with RPMI with 0.5% of FBS. Finally, cells
were seeded at a density of 1 × 106 in 200 µl of complete RPMI
and were stimulated with TLA (3 µg/well) or PMA (0.2 ng/well).
Non-stimulated cells were used as negative control. Proliferating
cell percentage was measured by FACScan flow cytometer at time
0 (basal), 24 and 48 h of incubation and data was analyzed with
CellQuest software. Results were expressed as mean fluorescence
intensity (MFI).
Statistical Analysis
Statistical analysis was performed by two-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparisons or one-
way ANOVA followed by Dunnet’s test using Prism 6.0 Software
(GraphPad, San Diego, California). P < 0.05 was considered
statistically significant. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p
< 0.0001; ns: represents not significant (p > 0.05).
RESULTS
Nanonanovesicles Structure
The Cryo-TEM images depicted in Figure 1A, showed
nanoARC-IMQ as heterogeneous populations, consisting
of 600–800 nm oligolamellar nanovesicles mixed with bigger
sized multilamellar nanovesicles; in Figure 1B LIPO-IMQ are
seen as oligolamellar vesicles having a dark material inside.
In coincidence with cryo-TEM images, DLS measurements
in Table 1 showed highly polydisperse nanovesicles of diameters
following the order: LIPO-IMQ > LIPO > nanoARC-IMQ
> ARC. Because of its negative Z potential, no electrostatic
association between TLA and nanovesicles occurred.
As shown in Figure 2A, sonication reduced the IMQ/PL ratios
from nanoARC-IMQ and LIPO-IMQ IMQ/PL. Notably, no
differences were found between IMQ/PL ratio from nanoARC-
IMQ measured in LH or Tris-HCl buffer washes, remaining
almost invariant after sonication, decreasing by ≈15% to 44
µg IMQ/mg PL and resulting nearly 20-folds higher than that
of LIPO-IMQ. This suggests that the IMQ was extensively
partitioned in the nanoARC bilayer, and that it was not detached
upon sonication. On the contrary the much lower IMQ/PL
ratio of LIPO-IMQ was sensitive to sonication, decreasing by
≈65% in Tris-HCl buffer to 5 µg IMQ/mg PL [data not
shown] and by ≈86% in LH to 2 µg IMQ/mg PL. In other
words, the sonication induced the loss of nearly 90% of the
IMQ in LIPO-IMQ while nearly half of quantified IMQ in
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FIGURE 1 | (A) Cryo-TEM image of nanoARC-IMQ+TLA, (B) Cryo-TEM image of LIPO-IMQ+TLA.
TABLE 1 | Structural characterization of nanovesicles.
Formulation Mean
diameter
(nm)
PDI
(mean ± SD)
Z potential
(mV)
IMQ/lipid
ratio
(µg/mg)
nanoARC 655 ± 271 0.62 ± 0.19 −42.6 ± 2.84
nanoARC-IMQ 850 ± 300 0.73 ± 0.18 −42.9 ± 1.87 44 ± 10
LIPO 1630 ± 269 0.56 ± 0.16 −3.3 ± 0.14
LIPO-IMQ 3614 ± 1787 0.73 ± 0.27 −5.4 ± 3.2 2.5 ± 1.5
TLA 6600 ± 1500 0.60 ± 0.20 −12 ± 0.5
Values are expressed as mean ± SD (n = 3 batches).
PDI, Polydispersity Index; SD, standard deviation.
Tris-HCl buffer was co-precipitated with the LIPO-IMQ pellet
free IMQ. The encapsulation efficiency of IMQ was ≈38%
in ARC-IMQ and ≈1% in LIPO-IMQ. As hypothesized by
Fox et al. (2014), nanovesicles with a LH acid core would
facilitate encapsulation of soluble IMQ while the bulk aqueous
phase of nanovesicles remains close to a neutral pH, which is
desirable to minimize injection pain (Fransson and Espander-
Jansson, 1996). Here a LH solution of IMQ was used to hydrate
the lipid films. However, despite of the reported low H+
permeability of ARC compared to that of liposomes (Yamauchi
et al., 1993), upon centrifugation washes no acid media was
detected within the vesicles (data not shown). The initial
huge osmotic gradient, -in the order or several pH units-
established across the nanovesicles bilayers along Tris-HCl buffer
washes, may have induced swelling and further inner content
leakage. Unless the IMQ was partitioned in bilayers, most
of soluble IMQ would be removed upon leakage and washes
(Figure 1B).
Figure 2B on the other hand, depicted the resultant of
submitting the vesicles to 3 sequential washes in Tris-HCl buffer,
aiming to assess a potential release of IMQ. Tough no significant
phospholipids content was found in the supernatants (data not
shown), different relative amounts of released IMQ were found
instead: while LIPO-IMQ lost ∼90% of its initial IMQ content,
only ∼10% of its initial IMQ content was lost from ARC-IMQ.
The samples volume submitted to centrifugation was 1,000 µl
and the pellet volume was ∼100 µl. Hence, it was observed that
ARC bilayers not only partitioned a higher amount of IMQ, but
that the IMQ remained associated in a higher extent in front to
a 1/10 folds dilution, than LIPO bilayers. This assay was aimed
to simulate the IMQ release from each type of lipid matrix and
represented a response to a potential dilution. In vivo however,
100 µl volume samples were injected in a virtual subcutaneous
space, suffering a practically negligible dilution. Overall, from a
structural point of view, ARC-IMQ would result better suited
than LIPO-IMQ to provide intracellular delivery of IMQ, since a
higher IMQ remained more strongly associated per mass of lipid
matrix, favoring thus its endocytic uptake.
Fluidity and Order of Bilayer Nanovesicles
The effect of IMQ on fluidity and order of nanoARC-IMQ
and LIPO-IMQ bilayers was assessed according to Altube et al.
(2017). To that aim, the fluorescent probe ofmembrane structure,
sensitive to the solvent relaxation effect Laurdan was employed
to determine generalized polarization (GP) and fluorescence
anisotropy (FA), respectively. As depicted in Figure 3, IMQ did
notmodify nanovesicles bilayers fluidity that showed identical FA
before and after IMQ loading. IMQ on the other hand, did not
affect the order of LIPO bilayers, but deeply reduced the typical
high disorder of ARC bilayers (Altube et al., 2017); the trend
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FIGURE 2 | (A) IMQ/PL ratio of nanovesicles before and after sonication in lactic acid (LH), (B) released IMQ in supernatant.
FIGURE 3 | (A) Laurdan fluorescence anisotropy (FA) and (B) generalized polarization (GP) of nanovesicles; bc: before centrifugation. Values are expressed as mean
± SD (n = 3 batches).
followed by the GP values was: nanoARC-IMQbc> nanoARC-
IMQ (finished formulation) > ARC. The GP of the more
ordered nanoARC-IMQbc bilayer was reduced after washing
loosely trapped IMQ in nanoARC-IMQ; in other words, the
order decreased as IMQ was removed. As shown in Table 1,
trapped IMQwas not observed to reduce the negative Z potential
of nanoARC-IMQ, despite of IMQ is positively charged at
acid/neutral pH (Chollet et al., 1999). Our results suggested
thus, that IMQ was partitioned modifying the order of the
archaeolipid bilayer, without relevant electrostatic interaction
between IMQ and the highly negative Z potential archaeolipid
bilayers. Opposite to ARC, neither fluidity not order of LIPO
bilayers were affected by IMQ, suggesting that IMQ was not
trapped into LIPO bilayers but dissolved in minute amount into
the aqueous space. This could account for the low IMQ/PL ratio,
encapsulation efficiency, and structural sensitivity to sonication
of LIPO-IMQ.
Nanovesicles Cytotoxicity and Induction of
TNF-α and IL-6 on J774A.1 Macrophages
In Figure 4A the cytotoxicity of nanoARC-IMQ, LIPO-IMQ, ISA
763, and IMQ upon 24 h incubation on the TLR7 (De Meyer
et al., 2012) SR-A1 (Todt et al., 2008) expressing macrophage
cell line J774A.1, is shown. The cell viability was not affected
between 0.5 and 5 µg IMQ, 10-100 µg PL LIPO and LIPO-IMQ.
Five micrograms IMQ/100 µg PL for nanoARC-IMQ, and 100
µg nanoARC + 5 µg IMQ on the other hand, resulted relatively
toxic, reducing the cell viability by≈40%.
In Figure 4B is shown that, in line with the cytotoxicity assay
and independently of its IMQ content, the nanoARC treatment
reduced the relative number of cells adhered to substrate, but
did not induce significant morphological alterations. The cells
treated with LIPO on the other hand, seemed to suffer less drastic
changes.
NanoARC-IMQ, an internalizable SR-A1 ligand combined
with a TLR7 ligand, was expected to increase the production of
TNF-α and of IL-6 above that induced by IMQ or nanoARC.
However, at all the tested concentrations, nanoARC-IMQ, IMQ
and nanoARC induced comparable TNF-α titers (Figure 5A).
0.25 µg IMQ/100 µg PL LIPO-IMQ on the other hand,
induced even less TNF-α than 0.25µg/ml IMQ (Figure 5B).
Remarkably, 5 µg IMQ/100 µg PL nanoARC-IMQ was the only
formulation that increased the IL-6 titer nearly 4 folds above IMQ
(Figures 5C,D).
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FIGURE 4 | (A) Cell viability. J774A.1 cell viability upon 24 h incubation with free IMQ, nanoARC-IMQ and remainder IMQ formulations evaluated by MTT. Values are
expressed as mean ± SD (n = 3 batches). Asterisks represent statistical difference against medium (B) bright field microscopy of selected samples, 20X magnification.
DTH
In Figure 6A the swelling diameters induced upon 3 sc doses
of nanovesicles are shown. It was observed that nanoARC-
IMQ+TLA and ISA763+TLA induced equally pronounced
swelling or cell mediated local responses, higher than those
of the reminder IMQ formulations. Remarkably, the response
to nanoARC-IMQ+TLA surpassed those induced by free
IMQ+TLA and by nanoARC+ IMQ + TLA. This led us to
confirm that nanoARC-IMQ, and not the free IMQ alone or
mixed with nanoARC, improved the response to IMQ, a fact that
resulted in a higher DTH.
Opposingly, no differences in swelling diameter were observed
between LIPO-IMQ+TLA and LIPO+IMQ+TLA. The low
IMQ/PL ratio, much less extensive endocytic uptake of LIPO
compared to ARC (Altube et al., 2016), together with the almost
absent capacity of stimulating TNF-α and IL-6 on J774A.1
macrophages that rendered a less pronounced DTH on the other
hand, suggested that only ARC but not LIPO, would succeed in
modifying IMQ pharmacodynamics on target cells. Despite of
not all immunogens inducing DTH are associated to a protective
cell response (Nichols et al., 2002), a classical DTH reaction
is considered indicative of cellular protective response (Crowle,
1975), mediated by T helper 1 (Th1) cells or activated CD4+
T cells (Cher and Mosmann, 1987) and CD8+ cytotoxic T cells
(Kalish and Askenase, 1999).
Antigen-Specific Systemic IgG Titers and
IgG Isotypes
In Figure 6B the antigen-specific systemic IgG titers upon 3 sc
doses of nanovesicles are shown. Clearly, nanoARC-IMQ+TLA
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FIGURE 5 | Pro-inflammatory cytokines released by J774A.1 cells. (A,B) TNF-α and (C,D) IL-6 released upon 24 h of incubation free IMQ, nanoARC-IMQ and
remainder IMQ formulations. Values are expressed as mean ± SD (n = 3 batches). Asterisks denotes significant differences against IMQ.
induced the highest response. Remarkably, IMQ+TLA and TLA
alone induced a response ∼1.5 orders lower. No difference
was detected between IMQ+TLA and TLA, meaning that
IMQ was useless to raise systemic antibodies. Notably (despite
of administered by a different route) Aldara does not raise
CD4+ T cells or antibody responses either (Rechtsteiner et al.,
2005; Gogoll et al., 2012, 2016). ISA763+TLA on the other
hand, raised a less pronounced response. Our results differ
from those reported in Cargnelutti et al. (2016), that 36 days
after 3 sc 10 folds higher TLA dose/ Balb/C mice, found no
significant differences between responses to TLA and to the
TLR7/8 ligand, while ISA763+TLA doubled it. In Figure 6C the
IgG2a/IgG1 isotype ratio (indicative of Th1/Th2 polarization in
mice (Coffman et al., 1988) is shown. The isotype ratio was∼1 for
ISA763+TLA and∼0.5 for the remainder samples, meaning that
whereas ISA 763+TLA recalled a mixed response, nanoARC-
IMQ+TLA and the reminder groups would induce a humoral-
biased response. The more detailed studies described below were
aimed to compare nanoARC-IMQ with ISA763.
IFNγ in Splenocytes Supernatants and
Intracellular IL-10 and IL-12 Cytokines
In Figure 7A the production of IFNγ in splenocytes supernatant
from mice immunized with nanoARC-IMQ+TLA, ARC+TLA,
and ISA763+TLA, is shown. It was observed that all groups
equally responded to TLA stimulus inducing low IFNγ levels
(compared to those raised by concanavalin A), suggesting a mild
induction of Th1 effectors in all groups. Additionally, only in
the monocytes and DC region a mild nonspecific production of
IL-10 was observed (Figure 7B). Neither IL-10 (Figure 7C) not
IL-12 induction was observed in the lymphocytes region (data
not shown).
Splenocytes Surface Markers
As shown in Figure 8, despite of the mild IFNγ levels reported
above, no significant increase of CD4+ TL (A) markers or
CD11c+/CD11b+, marker of myeloid or classical dendritic cells
(D) was induced in any group. All groups showed a non-specific
increased expression of B220+/MHCII(I-Ad)+ (C), markers of
mature activated B lymphocytes expressing surface MHC class
II, capable of antigen processing and presentation to T cells
(Hoffman et al., 2016). However, ISA763+TLA and ARC+TLA
induced a pronounced decrease in CD8+ TL markers; only the
group immunized with nanoARC-IMQ+TLA maintained the
percentage of CD8+ TL cells at a slightly higher (tough not
statistically significant) than the control value.
Lymphoproliferation of Splenocytes
As shown in Figure 9, after 48 h the splenocytes experienced non-
specific proliferation (as observed in culture media incubation,
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FIGURE 6 | (A) DTH. Asterisks represent statistical difference between nanoARC-IMQ + TLA and nanoARC + IMQ + TLA and numeral represents statistical
difference between nanoARC-IMQ + TLA and IMQ + TLA (#p < 0.01). ns, no significant difference Values are expressed as mean ± SD (n = 3), (B) Serum anti-TLA
IgG titers at day 38 after 3 subcutaneous doses. Asterisks indicate significant differences between nanoARC-IMQ + TLA and remainder groups. Numerals indicate
significate differences between ISA 763+TLA and IMQ + TLA or TLA (#p < 0.05; # ′p < 0.01). The cross indicates significant differences between nanoARC+TLA
and IMQ + TLA (
†
p < 0.05). Values are expressed as mean ± SD (n = 3), (C) IgG2a/IgG1 isotype ratio at day 38. Asterisks indicate significant differences between
ISA 763 + TLA and the remainder groups. Values are expressed as mean ± SD (n = 3).
in the absence of TLA or PMA stimulus). The group
immunized with ISA763+TLA and stimulated with TLA,
however, experienced a lower lymphoproliferation than those
immunized with nanoARC-IMQ+TLA or nano-ARC+TLA.
DISCUSSION
The presence of perpendicular methyl groups in isopranyl chains
makes the archaeolipids bilayers packed loosely in comparison
with bilayers made of ordinary phospholipids (Yamauchi et al.,
2000). The lateral entanglement of methyl groups and the bulky
carbohydrate moieties from sugar headgroups connected by
hydrogen bonds (Róg et al., 2007), make the archaeolipids
bilayers highly disordered and also of low lateral mobility
(Kitano et al., 2003). Each archaebacteria gender on the other
hand, possesses a set of characteristic archaeolipids (Corcelli and
Lobasso, 2006). Specifically, the polar archaeolipids extracted
from Halorubrum tebenquichense, were identified by ESI-MS by
Higa et al. (2012) and ordered according to decrescent abundance
as: archaeol analogmethyl ester of phosphatidylglycerophosphate
(PGPMe), archaeol analog phosphatidylglycerol (PG),
(1-O-[α-D-mannose-(2′-SO3H)-(1′ α 2′)-α-D-glucose]-
2,3-di-O-phytanyl-sn-glycerol) (SDGD5) the cardiolipin
bis phosphatidylglycerol (BPG) and the glycocardiolipin
SDGD5PA (2′-SO3H)-Manp-α1,2Glcpα-1-1-[sn-2,3-di-
Ophytanylglycerol]-6-[phospho-sn-2,3-di-O-phytanylglycerol].
Recently the double negatively charged PGPMe, majoritarian
polar lipid in H. tebenquichense responsible for its high negative
Z potential of −40mV, was confirmed to be a ligand of SRA-1
and not of SRB (the phosphatidylcholine receptor) (Altube et al.,
2016).
Scavenger receptors are defined as “cell surface receptors
that typically bind multiple ligands and promote the removal
of non-self or altered-self targets” (Prabhudas et al., 2014). SR-
A1 is a scavenger receptor of expression mainly confined to
macrophages (Naito et al., 1991, 1992; Hughes et al., 1995),
with unusually broad ligand binding properties including diverse
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FIGURE 7 | (A) IFN-γ production and (B,C) cytoplasmic antibodies labeling IL-10 cytokines of splenocytes after 48 h stimulation with concanavalin A, TLA or culture
medium. (B,C) correspond to percentage media of activated cell [MHCII(I-Ad)+] expressing IL-10 in the (B) monocytes and DCs and in (C) the lymphocytes regions,
respectively. Asterisks indicate significant differences between ISA 763 + TLA and the reminder groups. Numerals indicate significant differences between ConA and
TLA or medium. Values are expressed as mean ± SD (n = 3 mice per group).
types of negatively charged proteins, lipoproteins, nucleic acids,
and polysaccharides (Goldstein et al., 1979 and Plüddemann
et al., 2007). Remarkably, depending on the chemical nature
of internalized ligand and on the microenvironment, the SR-
A1 mediates either inflammatory (by secreting a spectra of
pro-inflammatory cytokines) or counteracting proinflammatory
receptors (Cotena et al., 2004).
Ligands internalization mediated by SR-A1 lacks- unless
in case of stressed ER-, of negative feedback, being typically
highly extensive (de Winther et al., 2000). Because of its content
on SR-A1 ligand PGP-Me, nanovesicles and nanoparticles
containing polar archaeolipids from H. tebenquichense
experience extensive internalization as well, compared to
the less pronounced of ordinary liposomes (Altube et al.,
2016; Higa et al., 2017). Overall, the presence of these
archaeolipids into otherwise labile nanovesicles not only
avoids cumbersome chemical derivatization required for ligands
linkage but provides nanovesicles with a higher tolerance to
physicochemical stress (heat sterilization and storage under
cold-free conditions, chemoenzymatic attacks (Caimi et al., 2017;
Higa et al., 2017) than ordinary liposomes, constituting also an
efficient mean to increase the intracellular delivery of loaded
cargo.
In this scenario, the idea of employing SR-A1-targeted
nanoARC carrying IMQ as immunomodulatory adjuvant, has
two important implications. The most obvious is counting
on a soft carrier, resistant to physicochemical and enzymatic
attacks, to which bilayers the IMQ was strongly associated. Such
interaction would reduce the chances of release and spreading of
free IMQ before target cells internalization, as occurs with the
current (particulate or not) IMQ formulations. The extensively
internalized nanoARC-IMQ leads to an extensive endosomal
delivery of IMQ to its TLR7. The other, most difficult to
assess, results from the endocytic processing of nanoARC-IMQ
by the complex indirect signaling route mediated by SR-A1.
Overall, in a first approach, the outcome of delivering the
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FIGURE 8 | Surface cell markers. Non-stimulated splenocytes from nanoARC-IMQ+TLA, nanoARC+TLA and ISA+TLA vaccinated mice were used to assess the
phenotypical expression of cell markers. (A) CD4T Lymphocytes. (B) CD8T Lymphocytes. (C) Activated B Lymphocytes (B220+/MHCII(I-Ad)+). (D) CD
CD11c+/CD11b+. The graphic shows the percentage average of positive cells for each marker. Asterisks indicate significant differences between
nanoARC-IMQ+TLA and the remainder groups. Numerals indicate significant differences between non-immunized and the reminder groups (#p < 0.05; # ′p < 0.01).
FIGURE 9 | Lymphoproliferation assay. Each sample was examined by triplicate and each bar is the media ± SD of 2 mice per group. Asterisk indicates significant
differences between cells stimulated respect to the control with culture media.
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IMQ to macrophage endosomes via SR-A1, would result in a
modification of IMQ cytotoxicity and cytokine titers elicited
in vitro as compared to the IMQ. After that, a different in vivo
response is expected.
Our most relevant first finding was that compared to
liposomes, nanoARC bilayers resulted excellent traps for IMQ:
the IMQ/PL ratio of nanoARC-IMQ was nearly 20 and
10 folds higher, respectively, than those of LIPO used in
this study and DPPC:DPPG:Chol nanoliposomes reported by
Fox et al. (2014). The huge IMQ/PL ratio of nanoARC-
IMQ may result from the particular structural features of
ARC bilayers that became more ordered upon IMQ insertion.
Probably the perpendicular methyl groups of archaeolipids
would account for IMQ trapping, in a fashion like the interaction
between IMQ and ramified isostearic acid (ISA). ISA is a
mixture of branched (mostly methyl-branched) and straight-
chain isomers of C18, C16, and C14 saturated fatty acids of
the general formula C17H35COOH. ISA is less susceptible to
color change and oxidation than the unsaturated fatty acids
and has many of the properties of stearic acid. However,
it has the fluidity and solubilizing properties of oleic acid
(Chollet et al., 1999) employed in the commercial formulation
Aldara (Walter et al., 2013). Counting on particles of high
drug/carrier ratio is important because at equal uptake rate,
carriers with higher drug/carrier ratio will provide a higher drug
delivery/time.
Upon 24 h, nanoARC-IMQ was found to be more cytotoxic
to J774A.1 macrophages than free IMQ. Its higher toxicity
would result from the massive endocytic delivery of carried
IMQ: while ordinarily IMQ diffuses across the cell membrane
driven by its concentration gradient, endocytosed nanoARC-
IMQ would provide a faster and massive endosomal delivery
of IMQ. Such higher intracellular delivery of IMQ would be
responsible for increased cytokines production by nanoARC-
IMQ compared to IMQ. The IMQ is known to activate
macrophages and other immune cells by inducing local cytokines
some of which are crucial for maturation of APCs such as
IFN-α, TNF-α, IL-1α, IL-1b, IL-6, IL-8, IL-10, via MyD88-
dependent signaling pathway (Eng et al., 2018) with a threshold
concentration for human peripheral blood monocyte cell PBMCs
includedmacrophages of 0.5µg/ml (∼2µM) (Gibson et al., 1995;
Testerman et al., 1995; Stanley, 2002). Besides, upon SR-A1 ligand
internalization, RAW264.7 macrophages induce TNF-α, IL-6,
and other proinflammatory and anti-inflammatory cytokines
such as IL-10 in a pattern depending on the type of ligand (Coller
and Paulnock, 2001). Here we observed that both nanoARC (a
SRA1 ligand) and nanoARC-IMQ (a SR-A1 and TLR7 ligand)
induced TNF-α on J774A.1 macrophages and that 5 µg IMQ/ml
nanoARC-IMQ was 4–6-folds more efficient inducer of IL-6
than 5 µg IMQ/ml. On the other hand, LIPO and LIPO-IMQ
were less cytotoxic than nanoARC-IMQ, but barely stimulated
TNF-α and did not induce IL-6. Since LIPO are not ligand
of SRA1, the TNF-α induced by LIPO-IMQ was owed to the
loaded IMQ. Moreover, 10 µg ARC/ml nanoARC (without IMQ,
10 folds lower lipid concentration than LIPO-IMQ), induced
TNF-α in macrophages as well. NanoARC therefore, was more
efficient TNF-α inducer than LIPO-IMQ; nano-ARC-IMQ on
the other hand, was more efficient IL-6 inducer than IMQ and
LIPO-IMQ.
Overall, these in vitro results suggested that, owed to their
high IMQ/PL ratio, the highly SR-A1-mediated internalized
nanoARC-IMQ, magnified the effect of IMQ on TLR7 expressing
macrophages. It was followed that in vivo, the outcome could be
an improved adjuvancy compared to IMQ.
The first set of sc administrations confirmed this presumption,
since nanoARC-IMQ+TLA and ISA763+TLA induced the
highest DTH compared to IMQ, that alone or in other any
combination induced less pronounced reactions. The second set
of sc administrations showed that nanoARC-IMQ+TLA induced
the highest antigen-specific systemic titers, probably because of
the modified pharmacodynamics of IMQ, as proposed above.
The last section compared nanoARC-IMQ+TLA with ISA
763+TLA. The water in (metabolizable, non-mineral) oil
emulsion, stabilized with mannitol, and purified oleic acid from
vegetable origin ISA 763 (MONTANIDE, 2017), can stimulate
both humoral and cell mediated immune responses, and is
considered safer than other mineral oil based Montanides. The
use of Montanides in general however, is associated with several
deleterious side effects (Skinner et al., 2008; Aunsmo et al.,
2009; Haugarvoll et al., 2010). In vitro, we found that ISA
763 was a poor inducer of TNF-α or IL-6 at the tested dose
(Figures 5A,C). In vivo, we found that nanoARC-IMQ+TLA
and ISA 763+TLA induced almost identical responses. Besides of
generating similar DTH and systemic IgG titers, both stimulated
low levels of IFNγ, a cytokine that controls the differentiation
of naive CD4+ T cells into Th1 effectors (Alving et al.,
2012) but without measurable increase of TL CD4+ cells. As
expected, the isotype ratio of ISA763+TLA was ≈1 (indicative
of cellular and humoral response), but the decreased CD8+
TL expression and lymphoproliferation after TLA stimulus,
suggested the occurrence of late deleterious effect. On the
contrary, while displaying an isotype ratio of ≈0.5 (indicative
of a humoral biased response), nanoARC-IMQ+TLA neither
reduced lymphoproliferation or CD8+ TL expression 10 days
after the last dose; on the contrary this last was slightly increased
compared to the control. These preliminary results suggest that
nanoARC-IMQ impacted on the innate immunity, adding IL-
6 to the TNF-α induced by IMQ on J774A.1 macrophages.
The activity of nanoARC-IMQ+TLA on Balb/C mice resulted
in a more intense Th2-biased response than the induced by
IMQ+TLA, accompanied with a CD8+ component, without
deleterious effects associated to ISA76+TLA. Further studies
will assess the existence of the proposed reduced systemic
bioavailability and in vivo adverse effects provided by nanoARC-
IMQ, as well as the outcome of higher doses of nanoARC-IMQ
on CD8+ TL.
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